Major depressive disorder
Conditions
Interventions
Major depressive disorder:Escitalopram treatment
Healthy control:none
Sponsors
Beijing Anding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Criteria for patients with major depressive disorder: 1) Outpatients aged 18-65 (including 18 and 65), regardless of gender; 2) Meeting the diagnostic criteria for major depressive disorder of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5), first episode or relapse, without psychotic symptoms; 3) No antidepressants taken for at least 14 days before enrollment; 4) Total score of HAMD-17 >=14; 5) Both biological parents were Han; 6) Primary school education or above, which could understand the content of the scale; 7) No contraindications for MRI scanning, such as implantation of electronic and metal instruments; 8) The informed consent were singed by patients with major depressive disorder. Criteria for healthy controls: 1) Aged 18-65 (including 18 and 65), regardless of gender; 2) Primary school education or above, which could understand the content of the scale; 3) Both biological parents were Han; 4) No contraindications for MRI scanning, such as implantation of electronic and metal instruments; 5) The informed consent were singed by healthy control.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients with major depressive disorde (meet 1 can be excluded) : 1) previous manic or hypomanic episodes; 2) Previous diagnosed with bipolar disorder, schizophrenia, schizoaffective disorder, anxiety disorder, and other disorders associated with mental disorders; 3) Patients with a history of alcohol dependence and acute intoxication; 4) Pregnant or lactating female patients; 5) For patients considered by researchers to be at serious risk of suicide, HAMD-17 suicide risk item was greater than or equal to 3 points; 6) At present, researchers with serious physical diseases not suitable for inclusion; 7) Patients who were intolerant to escitalopram in the past or did not respond to treatment. Exclusion criteria for healthy control : 1) Currently suffering from mental diseases; 2) History of consciousness disorder, schizophrenia or personality change; 3) Family history of inherited diseases; 4) serious physical diseases, endocrine system diseases and cardiovascular and cerebrovascular diseases; 5) A history of alcohol/drug dependence; 6) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate;The reduction of the total score of HAMD-17 from the baseline;Analysis of clinical features at baseline;Changes in cognitive functioning assessment scores;Other important time outcome rate: mania conversion rate, in line with DSM-5, hypomania, mania, mixed episodes;Adverse reactions: incidence of drug-related adverse events;MRI index;The reduction of the total score of PHQ-9 from the baseline;The reduction of the total score of QIDS-SR 16 from the baseline;Other important time outcome rate: Hospitalisation, for psychiatric episodes;Other important time outcome rate: self-inflicted suicidal behaviour;Changes in social functioning assessment scores; | — |
Countries
China
Contacts
Public ContactGang Wang
Beijing Anding Hospital, Capital Medical University
Outcome results
None listed